2023
T102. IDENTIFYING NEW TREATMENT TARGETS FOR ALCOHOL USE DISORDER THROUGH GENETIC AND ELECTRONIC HEALTH RECORDS DATA APPROACHES
Gray J, Kranzler H, Leggio L, Piserchia Z, Winterlind E, Setzer M, Rentsch C. T102. IDENTIFYING NEW TREATMENT TARGETS FOR ALCOHOL USE DISORDER THROUGH GENETIC AND ELECTRONIC HEALTH RECORDS DATA APPROACHES. European Neuropsychopharmacology 2023, 75: s217. DOI: 10.1016/j.euroneuro.2023.08.386.Peer-Reviewed Original ResearchSeed genesGenome-wide significant lociL-type calcium channel blockerDisease-associated genesCalcium channel blockersAlcohol use disorderTargets of approved drugsPeripheral genesSignificant lociCausal genesGene identificationGene inputNetwork genesGenetic supportBiological networksChannel blockersGenesUse disorderDisease mechanismsFDA-approved drugsL-type calcium channelsRegulate dopamine activityImprove drug developmentAlpha-adrenergic receptorsSevere side effectsAlcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisConverging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder
Farokhnia M, Rentsch C, Chuong V, McGinn M, Elvig S, Douglass E, Gonzalez L, Sanfilippo J, Marchette R, Tunstall B, Fiellin D, Koob G, Justice A, Leggio L, Vendruscolo L. Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder. Alcohol 2023, 109: 83-84. DOI: 10.1016/j.alcohol.2023.03.071.Peer-Reviewed Original ResearchRacial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
Vickers-Smith R, Justice A, Becker W, Rentsch C, Curtis B, Fernander A, Hartwell E, Ighodaro E, Kember R, Tate J, Kranzler H. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans. American Journal Of Psychiatry 2023, 180: 426-436. PMID: 37132202, PMCID: PMC10238581, DOI: 10.1176/appi.ajp.21111097.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol consumptionAUD diagnosisHispanic veteransWhite veteransUse disordersPrevalence of AUDAlcohol Use Disorders Identification TestUnhealthy alcohol useICD-10 codesAUDIT-C scoresSelf-reported alcohol consumptionAlcohol-related disordersDiagnosis of AUDDisorders Identification TestMaximum scoreSelf-reported raceElectronic health recordsPrimary outcomeAlcohol consumption levelsPotential confoundersHigh prevalenceMillion Veteran ProgramGreater oddsICD-9Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans
Naps M, Leong S, Hartwell E, Rentsch C, Kranzler H. Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans. Alcohol Clinical And Experimental Research 2023, 47: 438-447. PMID: 36810985, DOI: 10.1111/acer.15011.Peer-Reviewed Original ResearchConceptsSerum bicarbonate concentrationAlcohol use disorderMetabolic acidosisMEq/LAlcohol consumptionTopiramate therapyAlcohol Use Disorders Identification Test-Consumption scoresVeterans Health Administration electronic health record dataBicarbonate concentrationPropensity score-matched control groupPropensity score-matched controlsMean daily dosageSignificant metabolic acidosisElectronic health record dataDiagnosis of AUDHealth record dataBaseline alcohol consumptionDifferences linear regression modelThree-level measureAcid-base balanceTopiramate dosageTopiramate prescriptionsMean followTopiramate treatmentDaily dosage
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisSpironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry 2022, 27: 4642-4652. PMID: 36123420, PMCID: PMC10231646, DOI: 10.1038/s41380-022-01736-y.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-ConsumptionEffect of spironolactoneAlcohol consumptionSpironolactone doseNovel pharmacotherapiesUse disordersHuman studiesLarge integrated healthcare systemHeavy episodic alcohol consumptionAlcohol-induced ataxiaMineralocorticoid receptor antagonistsSelf-reported alcohol consumptionBlood alcohol levelsEpisodic alcohol consumptionIntegrated healthcare systemPharmacoepidemiologic cohort studyPotential new pharmacotherapiesCohort studyAlcohol drinkingReceptor antagonistFemale miceFemale ratsNew pharmacotherapiesRat modelAssociation of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data
Kranzler HR, Leong SH, Naps M, Hartwell EE, Fiellin DA, Rentsch CT. Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. Addiction 2022, 117: 2826-2836. PMID: 35768956, PMCID: PMC10317468, DOI: 10.1111/add.15980.Peer-Reviewed Original ResearchConceptsAUDIT-C scoresAlcohol use disorderElectronic health record dataHealth record dataUse disordersNEG patientsTopiramate dosageAlcohol Use Disorders Identification Test-Consumption scoresPropensity score-matched groupsHistory of AUDParallel group comparisonPropensity score-matched comparison groupRecord dataBaseline drinking levelsReduced alcohol consumptionHealth care systemTopiramate prescriptionsPre-post differencesAUD historyTopiramate's effectsPatientsRecord diagnosisAlcohol consumptionTopiramateComparison group
2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh risk
2019
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive days